Mineralys Therapeutics Outlines December PDUFA Date and Lorundrostat Launch Strategy
Mineralys Therapeutics (MLYS) has confirmed that its PDUFA target date for regulatory decision-making is set for December 22. The company is currently shifting its operational focus toward final launch preparations to ensure readiness for the commercialization of lorundrostat. Management indicated that funding strategies are being structured to support the product's market entry, which is projected to extend into 2028. This timeline reflects a long-term approach to scaling the drug's availability and managing capital requirements through the launch phase.
Tickers: $MLYS
Topics: Biotechnology PDUFA date Product Launch